Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.07.07.736943

Restricted MHC-II trafficking in Mycobacterium tuberculosis-infected M2-like macrophages limits CD4+ T cell activation

Abstract

Recognition of infected macrophages by CD4+ T cells is essential to immune protection against Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB). However, not all infected macrophage subsets successfully elicit T cell activation. We recently discovered that M2-like macrophages fail to efficiently activate memory CD4+ T cells when infected with Mtb, yet successfully elicit T cell activation when loaded with peptides, {gamma}-irradiated bacteria, or Mtb whole cell lysate. Since the mechanisms underlying CD4+ T cell evasion by infected M2 but not M1-like macrophages remain underexplored, we sought to determine the genes and pathways unique to Mtb infection of M2-like cells, including alveolar macrophages. RNA sequencing of human macrophages infected with virulent Mtb identified enrichment of IL-10 and type I interferon (IFN) signaling genes, including IL10RA and HERC5, respectively, in infected M2-like monocyte-derived and alveolar macrophages. However, genes involved in MHC-II trafficking, such as AP1M2, were higher in infected M1-like macrophages. In complementary experiments using fluorescence microscopy and flow cytometry, we observed impaired trafficking of newly synthesized MHC-II to the plasma membrane of Mtb-infected M2-like macrophages despite high total surface MHC-II levels. Neutralization of IL-10 or knockdown of HERC5 restored MHC-II trafficking to the cell surface among infected M2-like macrophages and significantly enhanced activation of memory CD4+ T cells in an MHC-II-dependent manner. These findings identify coordinated IL-10 and type I IFN signaling as key mechanisms that restrict MHC-II trafficking to the plasma membrane in Mtb-infected M2-like macrophages, thereby limiting antigen presentation and CD4+ T cell activation. We propose that host-directed therapies targeting these pathways in infected alveolar macrophages will facilitate T cell recognition for the prevention or treatment of active TB. Author SummaryRecognition of infected macrophages by CD4+ T cells is essential to immune protection against Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB). However, not all infected macrophage subsets successfully elicit T cell activation. We recently discovered that M2-like macrophages fail to efficiently activate memory CD4+ T cells when infected with Mtb, yet they successfully elicit T cell activation when treated with peptides, {gamma}-irradiated bacteria, or Mtb whole cell lysate. In this study, we identified genes and pathways uniquely upregulated in Mtb-infected M2-like macrophages that are linked to inefficient CD4+ T cell activation, including IL-10 signaling and type I interferon (IFN) pathways. These pathways were linked to reduced MHC-II trafficking to the plasma membrane in Mtb-infected M2-like macrophages. Neutralization of IL-10 or knockdown of HERC5 restored MHC-II trafficking and augmented memory CD4+ T cell activation. Our study demonstrates that IL-10 signaling and type I IFN pathways play detrimental roles in macrophages during Mtb infection, impairing MHC-II trafficking and CD4+ T cell activation. Since lung-resident alveolar macrophages express a dominant M2-like phenotype, these findings suggest that targeting IL-10 and type I IFN signaling may offer a strategy to enhance CD4+ T cell-mediated immunity and improve TB outcomes.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Sandhu, A. K., Gail, D. P., Simmermon, R. C., Webb, D., Hmiel, L., Bark, C., Bryson, B., Silver, R. F., Carpenter, S.. 2026-07-10. Restricted MHC-II trafficking in Mycobacterium tuberculosis-infected M2-like macrophages limits CD4+ T cell activation. https://doi.org/10.64898/2026.07.07.736943

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Exploratory positional differences in observed CDRH2 lineage-state transitions following HIV-1 germline-targeting vaccination

Background: Germline-targeting HIV-1 vaccination recruits VRC01-class B-cell precursors, but the positional patterns of observed longitudinal B-cell receptor lineage-state changes remain incompletely described. We compared CDRH2 profiles between homologous and heterologous boosting regimens using published IAVI G002 data. Methods: Participant-specific Week-8 lineages were prospectively matched to Week-24 observations. Germline-to-nongermline changes in sampled lineage-modal residues were evaluated at seven IGHV1-2*02 CDRH2 positions using participant-balanced, mean-centered profiles and exact participant-label permutation inference. Sampling-depth and sorting-probe sensitivity analyses assessed observability. A separate participant-held-out benchmark evaluated antibody-language-model representations for predicting observed Week-24 lineage detection. Results: The CDRH2 analysis included 332 lineages, 15 participants, 2,179 eligible lineage-position observations, and 241 observed state changes. The regional profile statistic was 0.027066 (exact p = 0.001709; six-region adjusted q = 0.010256), with descriptive differences at V-relative positions 51, 54, and 55. Most eligible longitudinal observations had one assessable cell per visit. In seven Group-1 participants, Week-24 dual-probe sampling recovered 181 baseline lineages with eOD-GT8 and 143 with Cg28v2, including 60 detected by both probes. In a separate cohort of 2,739 lineages from 17 participants, IgBERT and AbLang-2 representations did not improve participant-balanced average precision over a four-feature biological baseline. Conclusions: Observed CDRH2 lineage-modal-state profiles differed between regimens in this exploratory secondary analysis. Sparse sampling, potentially probe-related ascertainment, and absent linked functional validation preclude inference about mutation timing, functional improvement, or causal booster effects.

immunology↗

Multivalent mRNA tuberculosis vaccines protect against mycobacterial infection in zebrafish, mice and guinea pigs

Despite a century of BCG use, tuberculosis remains a leading cause of death from infectious diseases and more effective vaccines are urgently needed. Here we combined antigen discovery in zebrafish with mRNA vaccine technology to generate multivalent vaccine candidates, TUmRNA4, TUmRNA6 and TUmRNA9, encoding four, six, or nine Mycobacterium tuberculosis antigens, respectively. The vaccines were well tolerated, and induced robust antigen-specific cellular immune responses, including IFN{gamma} production and expansion of memory T-cell populations. In mice, TUmRNA4 and TUmRNA6 reduced pulmonary M. tuberculosis burden and lung pathology to levels comparable to BCG vaccination and TUmRNA6 enhanced BCG-mediated protection when used as a booster vaccine. In guinea pigs, TUmRNA9 reduced bacterial burden in the lungs, spleen, and lymph nodes and decreased pulmonary lesions. These findings demonstrate that protective antigens identified in zebrafish can be translated into effective multivalent mRNA vaccines and establish a framework for tuberculosis vaccine development across multiple preclinical models.

immunology↗

AlphaScreen profiling of extracellular vesicle-associated platelet, immune, and vascular markers reveals disease-specific signatures in ME/CFS, fibromyalgia, and long COVID

Introduction: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), and long COVID (LC-19) are chronic diseases with overlapping clinical features and poorly understood pathophysiology. Increasing evidence suggests the involvement of immune dysregulation, endothelial dysfunction, and altered vascular physiology. Extracellular vesicles (EVs) are key mediators of intercellular communication and are envisioned as sensors of homeostasis and disease. The aim of this study was to determine whether EV marker profiling could provide a basis for the differential diagnosis of ME/CFS, FM and LC-19 and/or patient stratification. Methods: EV-enriched plasma from ME/CFS, FM, cases co-diagnosed with ME/CFS and FM, LC-19 patients, and matched healthy controls (n = 10 per study group) were analyzed. EV concentration and size distribution were assessed by nanoparticle tracking analysis, followed by targeted profiling of EV-associated surface markers via AlphaScreen, including tetraspanins CD9 and CD63, platelet- (CD41/CD61), myeloid- (CD13), immune- (CD74 and CX3CR1), and renin-angiotensin system- associated ACE1 (also known as CD143), and ACE2 surface markers. Results: The studied disease groups presented distinct EV signatures. LC-19 samples exhibited the most pronounced and coordinated alterations, characterized by increased levels of CD9/CD74, CD9/CX3CR1, and CD9/ACE1-positive EVs, along with reduced overall particle concentrations. Notably, platelet-derived CD9/CD41/CD61-positive EVs were significantly elevated in both LC-19 and ME/CFS, as compared to healthy controls, indicating enhanced platelet activation. Immune-associated markers revealed differential pathway activation in LC-19, with CD74-positive EVs reflecting antigen presentation and inflammatory signaling, and CX3CR1-positive EVs indicating altered leukocyte trafficking and vascular interaction. Increased ACE1-positive EVs in LC-19 further suggested a shift toward pro-inflammatory renin-angiotensin signaling. Conclusion: Collectively, these findings support a disease-specific dysregulation of platelet, immune, and vascular pathways. The integrated EV signatures distinguish LC-19 from the related chronic conditions ME/CFS and FM, highlighting the potential of EV-based profiling for differential diagnosis. Our results provide a systems-level perspective on the differential pathophysiology of these disorders and identify EV-associated markers as candidate biomarkers with clinical value.

immunology↗